Drug discovery has always been a complex and expensive process, but one which provided potentially high rewards in exchange. However the burn-rate for pharmaceutical development costs has become difficult to sustain as the pipeline for new chemical entities (NCEs) and “blockbuster drugs” has significantly dried up, and the risk-to-reward ratio becomes tipped much less favourably. (more…)
Recent FDA action could expand the reach of type 2 diabetes (T2DM) drug rosiglitazone, better known as GlaxoSmithKline’s embattled Avandia. After years of controversy and warnings linking rosiglitazone to “potential” increased risk for cardiovascular events, the FDA is lifting some of the prescribing and dispensing restrictions first announced in September 2010. (more…)
The FDA Center for Drug Evaluation and Research (CDER), the American College of Gastroenterology, the American Gastroenterological Association, the Crohn’s and Colitis Foundation of America, Inc, the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, and the Pediatric IBD Foundation sponsored this workshop. Referred to as the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT II), this forum was created to consider the following issues: (more…)
Here are the top news stories and tweets across life sciences this week (December 2-6 2013).
A new report on pharmaceutical industry returns from Deloitte LLP and Thomson Reuters reveals the cost of bringing an asset from discovery to launch increased 18 percent between 2010 and 2013, and that the average forecast for peak sales of an asset declined by 43 percent.
This report is the fourth in an annual series exploring the pharmaceutical industry’s performance in generating a return from its investment in new product innovation. For the last four years Deloitte and Thomson Reuters have analysed the performance of the top 12 life sciences companies by estimating the projected financial returns from the investment in their late stage pipelines. (more…)
The latest The Ones to Watch report is an expert review of the most promising drugs launched from July to September 2013. These pharmaceuticals are changing clinical phase and receiving approval based on the strategic data and insight of Thomson Reuters Cortellis™ for Competitive Intelligence, an advanced source for timely and accurate Life Sciences information. (more…)
The World Generic Medicines Congress Americas organized by Health Network Communications brought generic pharmaceutical industry notables to the Revere Hotel in Boston’s Theater District for three days of workshops, presentations and round table discussions. Speakers included decision-makers from major generics industry players such as Hospira, Sandoz, Dr. Reddy’s and Wockhardt as well as experts in generic pharmaceutical law, financial investment, sourcing, purchasing and government regulation. This year again saw the concurrent hosting of the Biosimilar Drug Development World conference; general topic joint sessions were held Wednesday morning as well as Thursday with generics and biosimilars players splitting for more targeted presentations and discussions on Wednesday afternoon. The conference highlighted current challenges, emerging trends and future predictions for the global generic pharmaceutical industry. The concurrent conferences allowed for ample opportunity to compare and contrast the generics and biosimilars industries; discussion highlighted how commercial strategy, product development and regulatory hurdles challenged both small and large molecule manufacturers. (more…)
Getting a good night’s sleep is not a guarantee. Work obligations, life situations, and health issues are among the many possible distractions to catching some solid shut-eye. Rest eventually comes, usually on its own or with the help of medication such as sleeping pills. For people who are totally blind, however, the situation is more complicated. In these individuals, a lack of light perception means the body is unable to re-set (or, entrain) its internal circadian clock to the 24-hour day. This condition, non-24 hour sleep-wake disorder (Non-24), results in a disrupted sleep/wake cycle and a slew of related consequences to daily living. (more…)
To commemorate World AIDS Day, Thomson Reuters ScienceWatch, an open Web resource for science metrics and research performance analysis explored the contents of the more than 12,000 scientific and scholarly journals indexed within Thomson Reuters Web of Science to extract an elite selection of research reports on HIV and AIDS. This undertaking posed a particular challenge: given the volume of activity in the field—nearly 50,000 papers published over the last two years mention “HIV” or “AIDS”—how does one distinguish the truly consequential research? (more…)
Here is a rundown of the top life sciences news stories and tweets from this week (November 25-29th 2013).